Cardiff Oncology Inc. held its Annual Meeting of Stockholders on June 26, 2025. During the meeting, all seven nominees for director were elected. The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2025, was ratified. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable to 12,150,000 shares was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.